Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 3/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.40 |
| ▸ | FABP3 | P05413 | 3/20 | 0.39 |
| ▸ | FABP4 | P15090 | 3/20 | 0.39 |
| ▸ | MGLL | Q99685 | 5/20 | 0.37 |
| ▸ | APLNR | P35414 | 4/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | GCGR | P47871 | 1/20 | 0.36 |
| ▸ | KCNJ6 | P48051 | 1/20 | 0.36 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.36 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.36 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1131277 | 0.84 | MDM2 (0.48) | FABP3FABP4GCGR | |
| SCHEMBL1132019 | 0.79 | PTGS2 (0.40) | ESR1PTGS2FABP3FABP4MGLL | |
| SCHEMBL1132021 | 0.79 | PTGS2 (0.40) | ESR1PTGS2FABP3FABP4MGLL | |
| SCHEMBL1131611 | 0.77 | PTGS2 (0.43) | ESR1PTGS2FABP3FABP4GCGR | |
| SCHEMBL5861842 | 0.77 | PTGS2 (0.43) | ESR1PTGS2FABP3FABP4GCGR | |
| SCHEMBL4001179 | 0.77 | PTGS2 (0.47) | ESR1PTGS2FABP3FABP4GCGR | |
| SCHEMBL3883647 | 0.77 | PTGS2 (0.47) | ESR1PTGS2FABP3FABP4GCGR | |
| SCHEMBL1131499 | 0.74 | CNR1 (0.48) | ESR1KCNJ6KCNJ5KCNJ3 | |
| SCHEMBL1131253 | 0.73 | SLC5A1 (0.38) | — | |
| SCHEMBL18939425 | 0.72 | RPA1 (0.54) | FABP3FABP4KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1663105-B1 | CYCLOALKYL HETEROCYCLES FOR TREATING HEPATITIS C VIRUS | BRISTOL MYERS SQUIBB CO (US) | 2011-02-16 | — | — | EP | disclosed |